A Study of the Efficacy and Safety of 2PX in Patients With Pain Due to Oste... | Recruiting
A Study of the Efficacy and Safety ... | Recruiting
A Study of the Efficacy and Safety of 2PX in Patients With Pain Due to Osteoarthritis of the Knee

Trial Source

Location not identified by Google services

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Medical Conditions
  • Pain
  • Osteoarthritis
Robert Macnair, PhD
+44 1357 523481
See all trial contact details
Primary Contact Details
Recruiting
Recruitment Status
NCT00954629
Primary Trial ID Number

We need your help to advance medical research

You can help accelerate the discovery of cures of medical conditions by signing up and creating a profile. By doing so you can register your interest in clinical trials and researchers will be able to get in touch about trials that are suitable for you.

This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Summary
The purpose of the study is to demonstrate the superiority of topically administered 2PX versus placebo (vehicle) control in terms of reduction in pain intensity and physical function.
Research Details
  • Primary objective: To demonstrate the superiority of topically administered 2PX versus placebo (vehicle) control in terms of reduction in pain intensity and physical function.

    Secondary objectives: To prospectively measure other efficacy variables of topically administered 2PX in pain associated with osteoarthritis of the knee. To evaluate the safety and tolerability of topically administered 2PX.
Phase
Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Study Type
Interventional
Intervention
Drug : strontium chloride hexahydrate, Drug : Placebo

Study Arm Groups : 2PX, Placebo

Intervention Type
See Interventions above
Primary Outcome Measures
    The difference between the active and placebo group in the change from Baseline to the assessment after 26 weeks of treatment in the actual WOMAC Osteoarthritis Index LK 3.1 subscale score for pain and physical function.; 26 weeks
Secondary Outcome Measures
    WOMAC Osteoarthritis Index LK 3.1; total and non-pain subscales:; At Screening, Baseline, Weeks 2, 4, 12, 26 and 27.; Pain intensity will be assessed by asking the question 'What is the level of pain in your target knee right now?; Daily; Patient Global Impression of Change (PGIC); At weeks 12 and 26; Clinician Global Impression of Change (CGIC); At weeks 12 and 26; Use of rescue medication: The number of paracetamol tablets used each day will be recorded.; Daily; Incidence of Disease Flares: The number and extent of flares in osteoarthritis pain of the target knee between active and placebo groups during the course of treatment.; At weeks 2, 4, 12, 26, and 27
Publication(s)
Sorry, this information is not available
Result Reports
Check availability of results on the Clinicaltrials.gov website
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Gender
Both
Age Range
40 Years - N/A
Who Can Participate
Patients
Number of Participants
300
Participant Inclusion Criteria
    Inclusion Criteria:

    - Male and female out-patients, 40 years or older.

    - Subjects with documented OA of either one or both knees, as defined by the American College of Rheumatology (ACR) criteria ([Altman R, Asch E, Bloch D, et al (1986)]); i.e.knee pain and at least 3 out of the following 6 criteria in the target joint:

    - age >50 years

    - stiffness < 30 minutes

    - crepitus

    - bony tenderness

    - bony enlargement

    - no palpable warmth

    - Radiological evidence of joint space narrowing in the target joint within 8 weeks prior to randomisation.

    - Subjects with chronic, moderate to severe OA pain of the target knee:

    - present for more than 3 months, and for ≥ 20 days per month.

    - not controlled by, or intolerant of, oral NSAIDs, paracetamol, COX-2 inhibitors or weak opioids.

    - intensity at least moderate (i.e., actual WOMAC (pain questions 1-5) ≥ 10) on WOMAC OA index LK 3.1 at Visit 1, in the target knee, as recalled over the last 24 hours.

    Exclusion Criteria:

    - Subjects with any moderate to severe pain of other origin (e.g., fibromyalgia) which could confound assessment or self-evaluation of pain due to OA in the target knee.

    - Subjects with any prosthesis fitted to the target knee.

    - Subjects requiring treatment with any of the following agents/therapies within the specified periods or at any time during the study are excluded from participation:

    - Any potent/strong opioid in the 4 weeks prior to randomisation (i.e., an opioid assumed to cause withdrawal symptoms upon abrupt discontinuation).

    - Any topical or subcutaneously applied analgesic agents (e.g., capsaicin, NSAIDs) applied to the target knee within 7 days prior to randomisation.

    - Any treatment which could alter the degree or nature of baseline OA pain planned within the study period.

    - Intra-articular injections of corticosteroids in the target knee within the 2 months prior to randomisation.

    - Intra-articular injections of hyaluronan in the target knee within 6 months prior to randomisation.

    - Avascular necrosis in the target knee within 6 months prior to randomisation.

    - Arthrosynthesis of the target knee within 12 months prior to randomisation.

    - Arthroscopy of the target knee within 6 months prior to randomisation.

    - Major trauma to the target knee within 6 months prior to randomisation.

    - Infection in the target knee within 6 months prior to randomisation.

    - Subjects who have previously been treated with 2PX.

    - Subjects who have received an investigational drug or used an investigational device within the 30 days prior to randomisation.

    - Subjects with a significant psychiatric disorder, in the opinion of the investigator, or subjects receiving strong anti-psychotic medication.

    - Subjects with documented or suspected alcohol or drug abuse.

    - Any ongoing or past history of malignant disease within the 5 years immediately prior to randomisation (with the exception of basal cell carcinoma).

    - Pregnancy or ongoing lactation

    - Female subjects of childbearing potential unwilling to use adequate contraceptive measures throughout the duration of the study. For the purpose of this study, adequate contraception is defined as:

    - oral, injected or implanted hormonal methods of contraception; OR

    - placement of an intrauterine device (IUD) or intrauterine system (IUS); OR

    - barrier methods of contraception: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository Note: Male sterilisation or abstinence are not acceptable methods of birth control and would preclude enrolment in the study.

    Note: For post-menopausal women: less than 12 months since the last spontaneous menstrual bleeding will exclude the patient unless they are willing to utilise acceptable methods of contraception for the duration of the study.

    - Male subjects able to conceive, who are unwilling to use barrier methods of contraception throughout the duration of the study

    - Subjects unable to comply with the study assessments.
Participant Exclusion Criteria
This is in the inclusion criteria above
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Trial Location(s)
Manchester
Stonehill Medical Center
Bolton
Blackpool
Lancashire
Bradford Royal Infirmary
Bradford
Boehringer Ingelheim Investigational Site 75
Stockport
Trial Contact(s)
Primary Trial Contact
Robert Macnair, PhD
+44 1357 523481
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
Finland, Poland, Russian Federation, United Kingdom
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Scientific Title
A 26 Week Placebo-controlled, Randomised, Double-blind, Parallel Group Study of the Efficacy and Safety of 2PX (Topical Strontium Chloride Hexahydrate) in Patients With Pain Due to Osteoarthritis of the Knee
EudraCT Number
Not available for this trial
Funder(s)
  • SantoSolve AS
Other Study ID Numbers
2PX-OA-03
Sponsor(s)
Smerud Medical Research International AS
Key Dates

Recruitment Start Date

Jun 2009

Recruitment End Date

May 2010

Trial Start Date
Date Not Available
Trial End Date
Date Not Available
Date Assigned

06 Aug 2009

Last Updated

22 Mar 2010